Endocrine Abstracts

Background: The use of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs) is increasing, but PRRT remains palliative at this time. Estrogen (E2) has been extensively linked to cellular proliferation and DNA repair in other cancers. Our aim is to determine whether NET cells are similarly affected by estrogen and whether inhibition of estrogen receptor alpha (ESR1) increases radiosensitivity of NET cells, which could improve PRRT response.<p class=...